| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/30/2014 | US20140030329 Methods for Treating Insomnia |
| 01/30/2014 | US20140030328 Dual release oral tablet compositions of dexlansoprazole |
| 01/30/2014 | US20140030327 Tamper resistant dosage forms |
| 01/30/2014 | US20140030326 Effervescent formulations comprising dexketoprofen |
| 01/30/2014 | US20140030325 Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid |
| 01/30/2014 | US20140030323 Controlled release of n-acetylcysteine (nac) for reduction of systemic and/or vascular inflammation |
| 01/30/2014 | US20140030322 Pharmaceutical compositions |
| 01/30/2014 | US20140030321 Solid pharmaceutical composition |
| 01/30/2014 | US20140030319 Antagonists Of The Oncongenic Activity Of The Protein MDM2, And Use Thereof In the Treatment of Cancers |
| 01/30/2014 | US20140030317 Modulation of cell fates and activities by phthalazinediones |
| 01/30/2014 | US20140030316 Transdermal administration of fentanyl and analogs thereof |
| 01/30/2014 | US20140030313 Treatment of menstrual pain and excessive menstrual blood loss by intravaginal administration of a low dose of antifibrinolytic or hemostatic agent in combination with non-steroidal anti-inflammatory drug |
| 01/30/2014 | US20140030312 Use of combination preparations comprising antifungal agents |
| 01/30/2014 | US20140030311 Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof |
| 01/30/2014 | US20140030308 Implants and procedures for promoting autologous stem cell growth |
| 01/30/2014 | US20140030307 New combination comprising n-acetyl-l-cysteine and its use |
| 01/30/2014 | US20140030294 Methods for increasing immune responses using agents that directly bind to and activate ire-1 |
| 01/30/2014 | US20140030289 Compositions comprising beta-caryophyllene and methods of utilizing the same |
| 01/30/2014 | US20140030282 Anti-cd79b antibodies and immunoconjugates |
| 01/30/2014 | US20140030281 Anti-cd22 antibodies and immunoconjugates |
| 01/30/2014 | US20140030280 Anti-cd79b antibodies and immunoconjugates |
| 01/30/2014 | US20140030279 Anti-cd22 antibodies and immunoconjugates |
| 01/30/2014 | US20140030277 Immunomodulating compositions and methods of use thereof |
| 01/30/2014 | US20140030273 Human antibodies and antibody-drug conjugates against cd74 |
| 01/30/2014 | US20140030266 Compositions and Methods for Diagnosing and Treating Diseases and Disorders Associated With D-DT |
| 01/30/2014 | US20140030263 Treatment of diffuse large-cell lymphoma with anti-cd20 antibody |
| 01/30/2014 | US20140030260 Methods and compositions to eliminate chronic lymphocytic leukemia and other hematologic malignant cells in stromal microenvironment for cancer therapy |
| 01/30/2014 | US20140030258 Therapeutic treatments based on administration of small rna fragments |
| 01/30/2014 | US20140030257 Agtr1 as a marker for bevacizumab combination therapies |
| 01/30/2014 | US20140030256 Benzoxazole kinase inhibitors and methods of use |
| 01/30/2014 | US20140030249 Pharmaceutical Compositions |
| 01/30/2014 | US20140030244 Extracts isolated from electroporated ambhibian oocytes and use thereof in treating diseases and disorders |
| 01/30/2014 | US20140030241 Nutritional compositions for increasing arginine levels and methods of using same |
| 01/30/2014 | US20140030233 Therapeutic Compositions and Methods |
| 01/30/2014 | US20140030224 Methods and pharmaceutical compositions for inhibiting influenza viruses replication |
| 01/30/2014 | US20140030223 Inhibitors of flaviviridae viruses |
| 01/30/2014 | US20140030209 Topical liquid agent for the treatment of dermatophytosis |
| 01/30/2014 | DE102012014581A1 Vitaminzubereitung Vitamin preparation |
| 01/30/2014 | CA2876508A1 Spiro-fused piperidine derivatives for use as inhibitors of the renal outer medullary potassium channel |
| 01/30/2014 | CA2876391A1 4-[5-(pyridine-4-yl)-1h-1,2,4-triazole-3-yl]pyridine-2-carbonitrile crystalline polymorph and production method therefor |
| 01/30/2014 | CA2875818A1 Pharmaceutical formulation for bedwetting and method of use thereof |
| 01/30/2014 | CA2874860A1 Pharmaceutical combinations of a cdk4/6 inhibitor and a b-raf inhibitor |
| 01/29/2014 | EP2690442A1 Marker for determination of sensitivity to anticancer agent |
| 01/29/2014 | EP2690438A1 Synthesis of diverse glycosylphosphatidylinositol glycans and glycolipids from toxoplasma gondii and their application as diagnostic markers and vaccines |
| 01/29/2014 | EP2690175A2 Compositions and methods for combined inhibition of mutant EGFR gene and IL-6 expression |
| 01/29/2014 | EP2690105A1 Mannose derivatives, a process for preparing the same and their uses as a drug |
| 01/29/2014 | EP2690104A1 Synthesis of diverse glycosylphosphatidylinositol glycans from toxoplasma gondii and their application as vaccines and diagnostics |
| 01/29/2014 | EP2690102A1 Bicyclic aza-amides for treatment of psychiatric disorders |
| 01/29/2014 | EP2690101A1 5-Anilinoimidazopyridines and Methods of Use |
| 01/29/2014 | EP2690096A1 Process for preparation of Bendamustine |
| 01/29/2014 | EP2690095A1 Aryl gpr120 receptor agonists and uses thereof |
| 01/29/2014 | EP2690094A1 Fused quinonic compounds |
| 01/29/2014 | EP2690088A1 Mixed crystal agomelatine (form-viii), preparation method and use thereof and pharmaceutical composition containing same |
| 01/29/2014 | EP2690087A1 New crystal form vii of agomelatine, preparation method and use thereof and pharmaceutical composition containing same |
| 01/29/2014 | EP2689782A1 Improving memory in subjects with mini-mental state examination of 24-26 |
| 01/29/2014 | EP2689781A1 Misoprostol composition |
| 01/29/2014 | EP2689780A1 Intermediates for aminodihydrothiazine derivatives substituted with a cyclic group |
| 01/29/2014 | EP2689779A1 Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk |
| 01/29/2014 | EP2689778A1 Derivatives of azaindoles or diazaindoles for treating pain |
| 01/29/2014 | EP2689777A2 Pharmaceutical composition for treating hepatic disease |
| 01/29/2014 | EP2689776A1 Use of l-butylphthalide in the manufacture of medicaments for prevention and treatment of cerebral infarct |
| 01/29/2014 | EP2689013A1 Compositions for inhibiting gene expression and uses thereof |
| 01/29/2014 | EP2688902A1 Derivatives of allopregnanolone and of epiallopregnanolone and uses thereof for treating a neuropathological condition |
| 01/29/2014 | EP2688901A1 INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10 |
| 01/29/2014 | EP2688899A1 Selective glycosidase inhibitors and uses thereof |
| 01/29/2014 | EP2688891A1 Benzoxazepin compounds selective for pi3k p110 delta and methods of use |
| 01/29/2014 | EP2688890A1 Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
| 01/29/2014 | EP2688888A1 Process for the production of a pemetrexed salt |
| 01/29/2014 | EP2688887A1 Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
| 01/29/2014 | EP2688886A1 Azole compounds as pim inhibitors |
| 01/29/2014 | EP2688884A1 Amorphous form of vilazodone hydrochloride and process for its preparation |
| 01/29/2014 | EP2688883A1 Novel pyrimidine derivatives |
| 01/29/2014 | EP2688882A1 Pyrazole compounds as crth2 antagonists |
| 01/29/2014 | EP2688881A1 New azaspirodecanone compounds as hsl inhibitors |
| 01/29/2014 | EP2688877A1 Solid state forms of cabazitaxel and processes for preparation thereof |
| 01/29/2014 | EP2688874A1 Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators |
| 01/29/2014 | EP2688873A1 Bis(fluoroalkyl)-1,4-benzodiazepinone compounds |
| 01/29/2014 | EP2688872A1 Amidopyrazole inhibitors of interleukin receptor-associated kinases |
| 01/29/2014 | EP2688871A1 Prodrugs of lxr modulating imidazole derivatives |
| 01/29/2014 | EP2688866A1 Trpv1 antagonists |
| 01/29/2014 | EP2688648A1 A 5-ht4 receptor agonist as a prokinetic agent |
| 01/29/2014 | EP2688595A2 Lin28-mediated control of let-7 biogenesis |
| 01/29/2014 | EP2688594A2 Methods and compositions for the treatment of cancer |
| 01/29/2014 | EP2688591A1 Dendritic cells (dcs) targeting for tuberculosis (tb) vaccine |
| 01/29/2014 | EP2688574A1 Method of screening antiretroviral compounds and vaccine |
| 01/29/2014 | EP2688573A1 A novel process for preparation of polysaccharides |
| 01/29/2014 | EP2688572A1 A pharmaceutical composition comprising a hdac inhibitor and a steroid and the use thereof. |
| 01/29/2014 | EP2688571A1 Myelin regeneration with androgens |
| 01/29/2014 | EP2688570A2 6-substituted estradiol derivatives for use in remyelination of nerve axons |
| 01/29/2014 | EP2688569A1 Treatment of solid tumours |
| 01/29/2014 | EP2688568A2 Cyclopropylamines as lsd1 inhibitors |
| 01/29/2014 | EP2688567A1 Autophagy inducing compound and use thereof |
| 01/29/2014 | EP2688566A2 Anticancer therapeutic agents |
| 01/29/2014 | EP2688565A1 Treatment of proliferative disorders with a chemiluminescent agent |
| 01/29/2014 | EP2688564A2 Calcium supplement |
| 01/29/2014 | EP2688563A1 Gallium complexes, pharmaceutical compositions and methods of use |
| 01/29/2014 | EP2688560A2 A composition comprising lipid nanoparticles and a corticosteroid or vitamin d derivative |
| 01/29/2014 | EP2688558A2 Oral complex composition comprising omega-3 fatty acid ester and hmg-coa reductase inhibitor |
| 01/29/2014 | EP2688557A1 Methods and compositions for treatment of attention deficit disorder |
| 01/29/2014 | EP2688556A2 Controlled release pharmaceutical dosage forms |